Clinical trial
A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
NCT04968574 is registered in ClinicalTrials.gov with Endeavor Biomedicines, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- Endeavor Biomedicines, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 26, 2021
- Completion date
- November 30, 2023
- Enrollment
- 41 (actual)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.